Saturday 17 October 2026 Export BMRN’s income statement to Excel — free account

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024. In the quarter to June 2026, revenue grew 19.9%, EPS fell 81.6%, free cash flow fell 20.3% and total debt rose 602.2%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

54.68 1.37 −2.44%

Follow BMRN

Alert me

Market cap: $10.9B
P/E: 144×
Fwd P/E: 16.1×
Dividend yield: —
F-score: 5/9
Altman Z: 5.67
Beneish M: −2.49
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
P/E ratio Full definition →	+8 more quarters Free account	19.91	32.65	40.35	150.58
P/S ratio Full definition →		3.36	3.54	3.35	3.25
P/FCF ratio Full definition →		12.59	15.90	14.32	15.27
P/Operating CF Full definition →		28.21	114.39	49.28	65.84
P/B ratio Full definition →		1.72	1.87	1.75	1.75
Price to Tangible BV Full definition →		1.85	2.01	1.87	14.07
EV/Sales Full definition →		3.24	3.39	3.26	4.22
EV/EBITDA Full definition →		14.45	22.57	27.46	48.35
EV/Operating CF Full definition →		10.96	13.20	12.10	16.78
EV/FCF Full definition →		12.13	15.24	13.93	19.84
Quick Ratio Full definition →		2.84	3.25	3.94	1.16
Current Ratio Full definition →		4.83	5.21	5.81	2.39
Net Debt/EBITDA Full definition →		27.62	38.11	(5.44)	15.85
Debt/Assets Full definition →		7.84%	7.86%	16.65%	35.71%
Debt/Equity Full definition →		0.10	0.10	0.23	0.66
Asset Turnover Full definition →		0.43	0.44	0.41	0.36
Operating CF/Net income Full definition →		(11.99)	(2.14)	2.09	3.76
Capex/Depreciation Full definition →		(2.28)	(2.23)	(1.31)	(0.35)
Interest Coverage Full definition →		(18.10)	(16.06)	8.67	1.75
Research and Development Expense of Revenue Full definition →		52.76%	22.00%	23.34%	20.91%
Selling, General and Administrative Expense of Revenue Full definition →		34.58%	51.02%	33.71%	39.97%
Intangible Assets out of Total Assets Full definition →		0.06	0.05	0.05	0.47
Share Based Compensation of Revenue Full definition →		6.35%	5.36%	5.67%	7.65%
Graham Net Nets Full definition →		0.22	0.21	0.20	(0.13)
Graham Number Full definition →		43.93	36.05	31.88	16.72
Earnings Yield Full definition →		5.02%	3.06%	2.48%	0.66%
Free Cash Flow Yield Full definition →		7.94%	6.29%	6.98%	6.55%
Revenue per Share Full definition →		4.04	4.56	3.98	5.12
Operating CF per Share Full definition →		1.92	0.52	1.15	0.87
Capex per Share Full definition →		(0.18)	(0.22)	(0.11)	(0.18)
Free Cash Flow per Share Full definition →		1.74	0.29	1.04	0.69
Cash per Share Full definition →		7.70	8.14	11.55	4.52
Shareholders Equity per Share Full definition →		31.54	31.74	32.27	32.68
Interest Debt per Share Full definition →		0.00	0.00	0.00	0.00
Book value per Share Full definition →		31.54	31.74	32.27	32.68
Free Cash Flow Full definition →		334.94	56.55	199.73	133.86
Working Capital Full definition →		3,056.11	3,194.46	3,811.92	2,307.63
Capital Expenditures Full definition →		(33.75)	(43.09)	(20.92)	(34.25)
Net Current Asset Value Full definition →		2,296.39	2,446.47	2,226.16	(1,430.13)
EV/EBIT Full definition →		16.27	26.69	33.55	96.34
Capex to Sales Full definition →		0.04	0.05	0.03	0.03
Price to Operating Income Full definition →		16.90	27.84	34.50	74.15
Other line items
Average Receivables Full definition →		783.91	784.37	821.55	958.45
Average Payables Full definition →		757.05	683.01	710.68	845.02
Average Inventory Full definition →		1,280.76	1,265.77	1,274.03	1,561.35
Average Assets Full definition →		7,233.03	7,291.48	7,869.01	9,589.89
Average Common Equity Full definition →		5,735.05	5,872.49	6,002.78	6,174.40

Show all line items

Columns are period end dates

Stockrow Weekly